CAR-iNKT cells kill their relevant antigen-expressing tumor cell lines or patient-derived plasma cells in vitro (129–132) and tumor xenograft models in vivo (129–131), maintaining their CD1d-dependent functions. Here, CD1D is linked to neoplasm.